GILD | Gilead Sciences Inc
Category: Biotechnology company
Quick infos Headquarters: Foster City, California, United States Trade prices Volume: 2.3M Market Cap: 78.22B Prev closed: 59.05 Open: 58.44 High: 61.45 Low: 58.18 52 week low: 57.04 52 week high: 85.97 Dividends: Next ER: April 27, 2023 After Market Closes
About the Company Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs.
Earnings History Date EPS / Forecast Revenue / Forecast August 1, 2023 April 27, 2023 1.37 / 1.536.4B / 6.31BBeat! February 2, 2023 1.67 / 1.57.4B / 6.66BBeat! October 27, 2022 1.9 / 1.527B / 6.13BBeat! August 2, 2022 1.58 / 1.526.26B / 5.86BBeat! view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company ISIN: US3755581036 CUSIP: 375558103 Founded:June 1987 Employees:9,000 News
Gilead slips after cutting 2023 earnings guidance seekingalpha.com Apr 28, 2023 4:48 am Gilead Sciences beats revenue estimates but misses profit consensus seekingalpha.com Apr 28, 2023 4:02 am Gilead set to continue revenue beat streak with Q1 results seekingalpha.com Apr 26, 2023 10:55 pm
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know finance.yahoo.com Feb 3, 2023 5:50 pm
UPDATE 1-Gilead buys out rights to cancer therapy from Jounce for $67 mln finance.yahoo.com Feb 3, 2023 5:31 pm
Gilead stock jumps 5% after Q4 beat, dividend increase finance.yahoo.com Feb 3, 2023 5:14 pm EU publishes proposed reforms for pharma industry seekingalpha.com Apr 26, 2023 9:26 pm What is behind biotech M&A resurgence? seekingalpha.com Apr 24, 2023 Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more seekingalpha.com Apr 22, 2023 1:30 am WHO chief expects COVID emergency to end this year seekingalpha.com Apr 7, 2023 2:14 am FDA forces pre-term birth drug off the market after 12 years seekingalpha.com Apr 7, 2023 12:35 am Gilead said to be in late-stage trials for oral COVID therapy seekingalpha.com Apr 5, 2023 9:29 pm CMS shortens list of drugs subject to new Medicare rebates in 2025 seekingalpha.com Apr 4, 2023 12:13 am Texas judge blocks Obamacare for free HIV drugs, cancer screenings seekingalpha.com Mar 31, 2023 12:05 am NuCana falls 36% after setback for patent dispute in EU for Gilead’s antiviral seekingalpha.com Mar 27, 2023 9:58 pm FDA draft guidance impacts companies using accelerated approval for oncology drugs seekingalpha.com Mar 25, 2023 1:01 am Gilead waives rights to acquire immune-oncology biotech Pionyr seekingalpha.com Mar 23, 2023 7:04 pm Gilead's Kite unit touts survival benefit of Yescarta in large B-cell lymphoma seekingalpha.com Mar 21, 2023 11:56 pm Gilead licenses protein degrader from Nurix Therapeutics seekingalpha.com Mar 20, 2023 10:01 pm AbbVie, Gilead, Seagen among firms fined for raising prices faster than inflation seekingalpha.com Mar 15, 2023 9:10 pm GILD Dividends Ex-Dividend Amount Announced Date Record Date Payment Date Mar 14, 2023 0.75 Mar 30, 2023 Dec 14, 2022 0.73 Dec 29, 2022 Sep 14, 2022 0.73 Sep 29, 2022 Jun 14, 2022 0.73 Jun 29, 2022 Mar 14, 2022 0.73 Mar 30, 2022 view more
Key Persons CEO : John F. Milligan, PhD Talk about Gilead Sciences Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Homepage: gilead.com Consensus BUY 44 HOLD 56 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written. -- Warren Buffet